Canyon Pharmaceuticals' DESIR-ABLE Study Completed
10/10/2012 8:56:06 AM
More...
|
Canyon Pharmaceuticals Announces Study Published in the Journal of Thrombosis and Haemostasis
6/20/2012 11:50:38 AM
More...
|
Canyon Pharmaceuticals Honored with Frost & Sullivan Award for Product Differentiation Excellence in Parenteral Anticoagulants
10/18/2011 8:18:42 AM
More...
|
Canyon Pharmaceuticals: Study Finds Desirudin Superior to Enoxaparin in Patients with Poor Kidney Function Undergoing Orthopedic Surgery
5/2/2011 8:44:34 AM
More...
|
Comparative Trial of Canyon Pharmaceuticals's Iprivask (Desirudin) with Standard of Care Shows Favorable Outcomes for Thrombosis Prophylaxis in Surgery Patients with HIT
4/15/2010 9:36:39 AM
More...
|
First Direct Thrombin Inhibitor for DVT Prevention Now Available From Canyon Pharmaceuticals
3/1/2010 10:30:03 AM
More...
|